- Home
- SILA vs EWTX Comparison
SILA vs EWTX Comparison
Compare SILA & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILA
- EWTX
- Stock Information
- Founded
- SILA 2013
- EWTX 2017
- Country
- SILA United States
- EWTX United States
- Employees
- SILA N/A
- EWTX N/A
- Industry
- SILA
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- SILA
- EWTX Health Care
- Exchange
- SILA NYSE
- EWTX Nasdaq
- Market Cap
- SILA 1.4B
- EWTX 1.2B
- IPO Year
- SILA N/A
- EWTX 2021
- Fundamental
- Price
- SILA $23.48
- EWTX $13.35
- Analyst Decision
- SILA Strong Buy
- EWTX Buy
- Analyst Count
- SILA 3
- EWTX 9
- Target Price
- SILA $28.67
- EWTX $39.89
- AVG Volume (30 Days)
- SILA 793.5K
- EWTX 983.7K
- Earning Date
- SILA 08-05-2025
- EWTX 08-07-2025
- Dividend Yield
- SILA 6.78%
- EWTX N/A
- EPS Growth
- SILA 45.68
- EWTX N/A
- EPS
- SILA 0.63
- EWTX N/A
- Revenue
- SILA $184,473,000.00
- EWTX N/A
- Revenue This Year
- SILA $7.93
- EWTX N/A
- Revenue Next Year
- SILA $9.13
- EWTX N/A
- P/E Ratio
- SILA $37.53
- EWTX N/A
- Revenue Growth
- SILA N/A
- EWTX N/A
- 52 Week Low
- SILA $20.43
- EWTX $10.60
- 52 Week High
- SILA $27.50
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- SILA N/A
- EWTX 34.22
- Support Level
- SILA N/A
- EWTX $12.15
- Resistance Level
- SILA N/A
- EWTX $14.85
- Average True Range (ATR)
- SILA 0.00
- EWTX 0.68
- MACD
- SILA 0.00
- EWTX -0.16
- Stochastic Oscillator
- SILA 0.00
- EWTX 23.13
About SILA SILA REALTY TRUST INC
Sila Realty Trust Inc is a real estate investment trust. Its investment objective is to pay regular cash distributions to stockholders and to preserve, protect, and return capital contributions to stockholders. The company owns and manages healthcare assets. The company generates revenue from real estate investments in healthcare properties.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.